COVID-19 Vaccine - EOI Update John Baillie
Description: COVID-19 Vaccine - EOI Update John Baillie Executive Manager HNECC PHN WE ACKNOWLEDGE THE TRADITIONAL OWNERS CUSTODIANS OF THE LAND THAT WE LIVE WORK ON AS THE FIRST PEOPLE OF THIS COUNTRY. These slides will be circulated after the
Related Topics
Download Presentation
"COVID-19 Vaccine - EOI Update John Baillie" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Presentation Transcript
slide1. COVID-19 Vaccine - EOI
Update
John Baillie
Executive Manager HNECC PHN
WE ACKNOWLEDGE THE TRADITIONAL OWNERS & CUSTODIANS OF THE LAND THAT WE LIVE & WORK ON AS THE FIRST PEOPLE OF THIS COUNTRY.<br>
slide2. These slides will be circulated after the webinar
Key local contacts
John Baillie jbaillie@hneccphn.com.au 0439944123
Kimberly Booth kbooth@hneccphn.com.au
Potential applicants can seek clarification on this EOI by sending an email to
primarycareCOVIDvaccine@health.gov.au
Questions and responses will be shared with all potential applicants if relevant/appropriate<br>
slide3. Vaccine status
COVID-19 vaccines COMIRNATY (BNT162b2[mRNA]) COVID-19 Vaccine (known as COMIRNATY (BNT162b2[mRNA]) COVID-19 Vaccine) now provisionally approved, with a rollout to priority groups in Phase 1a commencing mid / late February
(Fully imported - Note: competitive international market at play)
OXFORD / Astra Zeneca TGA approval expected by the end of this month, with a rollout to priority groups in Phase 1b – 2b
(Manufactured on shore = not so influenced by international markets)
MODERNA/ NOVAVAX /COVAX and others later in the year<br>
slide4. AMS and GPRC’s
different processopt out run via direct contract with DoH
General Practice
EOI Launched 22/01/2021 till 01/02/2021
Incremental increasing sites based on availability of vaccine supply AND ability to do volumes and at pace<br>
slide5. Phase 1a – Pfizer vaccine (transport and storage at <70 Celsius) 15-minute observation period TGA approval 25/01/2021 - One vial (0.45 mL) contains 6 doses of 0.3 mL after dilution,
Vaccine Hubs – one known so far = John Hunter Hospital + several in Sydney
Various lead agencies including LHD’s, private contracted providers (Aspen Medical, Healthcare Australia, International SOS, and Sonic Clinical Services)
Frontline at-risk health care workers including staff in GP respiratory clinics and COVID-19 testing facilities, ambulance staff, paramedics, ICU and emergency department staff and clinical and ancillary support staff
Residential aged care and disability care staff (including GP’s who visit facilities)
Residential aged care and disability care residents
Quarantine and border workers<br>
slide6. Phase 1b – Astra Zeneca vaccine (transport and storage 2 – 8 degrees Celsius) 15-minute observation expected ALL SUBJECT TO TGA APPROVAL
Anticipated MID MARCH onwards
Primary care lead with PHN’s playing major role in coordination and support
Adults over 70 years
All other health care workers
Begin to vaccinate Aboriginal and Torres Strait Islander people
Younger adults with an underlying medical condition, including those with a disability
Critical and high-risk workers including defence, police, fire, emergency services and meat processing.<br>
slide7. Primary care lead with PHN’s playing role in coordination and support
Phase 2a – Astra Zeneca vaccine (transport and storage 2 – 8 degrees Celsius) 15-minute observation expected ALL SUBJECT TO TGA APPROVAL
Adults over 50
Aboriginal and Torres Strait Islander people 18 - 54
Younger adults with an underlying medical condition, including those with a disability
Other critical and high risk workers. Phase 2b –Astra Zeneca vaccine (transport and storage 2 – 8 degrees Celsius) 15-minute observation expected ALL SUBJECT TO TGA APPROVAL
Remainder of the population
Catch up on people who have missed out<br>
slide8. Phase 3 – VACCINE Yet to be determined
People <18 YO (subject to further TGA approval)<br>
slide9. LIMITING FACTOR = Supply of vaccines
AIM = Delivery in volume and at pace aimed to the target cohort
Current advice 2 doses require 21 days / month apart must be same product
FREE for patient MBS Items and PIP (Exempt from 80/20 rule) GP and OMP
Co-billing being clarified
(no item number for authorised nurse immunisers)
Voluntary<br>
slide10. Selection criteria, processes and outcomes
The Commonwealth Department of Health will receive and review all EOIs according to the following criteria:
1. Capability: Accredited general practices who can provide safe vaccination services according to the specifications in Attachment A and willingness to undertake COVID-19 vaccination specific training.
2. Capacity and volume: Ability to administer, track, record, store, maintain and manage vaccination services with equitable access to all eligible people on a large scale, as per the site specifications outlined in Attachment A.
3. Lead Time: Ability to accelerate administration of vaccination services to meet nominated timeframes.
4. Population coverage and access: Additional consideration will be placed on practices servicing populations in low-access geographic areas or with specific access needs.<br>
slide11. Role of the Primary Health Networks
Primary Health Networks will assist in the coordination, planning and delivery of the vaccine roll-out, including playing a key liaison and support role with general practices. This will include collating and prioritising applications for consideration by the Department of Health according to preparedness (as nominated by the practice), providing information on local context and needs that will help to improve geographic coverage, and liaising with local and jurisdictional health authorities to minimise duplication of services.
Commonwealth DoH will ultimately decide<br>
slide12. OPT in
@1710 hrs 27/01/2020
70 EOI’s in the HNECC PHN region
1500 EOI’s nationally First submission @ 0946 23 January<br>
slide13. Known
Currently 1 Hub for 1a in the Hunter
Practice can withdraw EOI
Change or amend EOI by resubmitting and letting PHN know
Where practices want to pool resources, all should EOI and note this in the free text of all EOI’s seeking to collaborate Question 37 and 42
Unknown
Details on National booking system (this will be available by end of week)
Co-billing clarification in FAQ<br>
slide14. Resources and local
1. link to the NSW Health/RACGP Covid19 Update webinar on the COVID19 Vaccine held on 18 January 2021
– well worth grabbing a coffee or tipple of choice and watching it!
https://youtu.be/GxzgP-rh8Hk
2. Australia’s COVID19 Vaccine National Roll-Out Strategy for Phases of roll out priority groups & stratification
https://www.health.gov.au/sites/default/files/documents/2021/01/australia-s-covid-19-vaccine-national-roll-out-strategy.pdf
3. Central Coast GPs please join our Central Coast GP COVID Community of Practice as we focus on sharing vaccine planning and preparation. Lots of brainstorming to do! Entry via Basecamp:
https://3.basecamp.com/4489790/join/CgP7Fu2gz6kC
Contact Elly Warren or Karen Douglas if you have difficulty registering or have any questions and we will add you manually.
ewarren357@gmail.com
k.douglas1@bigpond.com<br>
slide15. Questions<br>
Update
John Baillie
Executive Manager HNECC PHN
WE ACKNOWLEDGE THE TRADITIONAL OWNERS & CUSTODIANS OF THE LAND THAT WE LIVE & WORK ON AS THE FIRST PEOPLE OF THIS COUNTRY.<br>
slide2. These slides will be circulated after the webinar
Key local contacts
John Baillie jbaillie@hneccphn.com.au 0439944123
Kimberly Booth kbooth@hneccphn.com.au
Potential applicants can seek clarification on this EOI by sending an email to
primarycareCOVIDvaccine@health.gov.au
Questions and responses will be shared with all potential applicants if relevant/appropriate<br>
slide3. Vaccine status
COVID-19 vaccines COMIRNATY (BNT162b2[mRNA]) COVID-19 Vaccine (known as COMIRNATY (BNT162b2[mRNA]) COVID-19 Vaccine) now provisionally approved, with a rollout to priority groups in Phase 1a commencing mid / late February
(Fully imported - Note: competitive international market at play)
OXFORD / Astra Zeneca TGA approval expected by the end of this month, with a rollout to priority groups in Phase 1b – 2b
(Manufactured on shore = not so influenced by international markets)
MODERNA/ NOVAVAX /COVAX and others later in the year<br>
slide4. AMS and GPRC’s
different processopt out run via direct contract with DoH
General Practice
EOI Launched 22/01/2021 till 01/02/2021
Incremental increasing sites based on availability of vaccine supply AND ability to do volumes and at pace<br>
slide5. Phase 1a – Pfizer vaccine (transport and storage at <70 Celsius) 15-minute observation period TGA approval 25/01/2021 - One vial (0.45 mL) contains 6 doses of 0.3 mL after dilution,
Vaccine Hubs – one known so far = John Hunter Hospital + several in Sydney
Various lead agencies including LHD’s, private contracted providers (Aspen Medical, Healthcare Australia, International SOS, and Sonic Clinical Services)
Frontline at-risk health care workers including staff in GP respiratory clinics and COVID-19 testing facilities, ambulance staff, paramedics, ICU and emergency department staff and clinical and ancillary support staff
Residential aged care and disability care staff (including GP’s who visit facilities)
Residential aged care and disability care residents
Quarantine and border workers<br>
slide6. Phase 1b – Astra Zeneca vaccine (transport and storage 2 – 8 degrees Celsius) 15-minute observation expected ALL SUBJECT TO TGA APPROVAL
Anticipated MID MARCH onwards
Primary care lead with PHN’s playing major role in coordination and support
Adults over 70 years
All other health care workers
Begin to vaccinate Aboriginal and Torres Strait Islander people
Younger adults with an underlying medical condition, including those with a disability
Critical and high-risk workers including defence, police, fire, emergency services and meat processing.<br>
slide7. Primary care lead with PHN’s playing role in coordination and support
Phase 2a – Astra Zeneca vaccine (transport and storage 2 – 8 degrees Celsius) 15-minute observation expected ALL SUBJECT TO TGA APPROVAL
Adults over 50
Aboriginal and Torres Strait Islander people 18 - 54
Younger adults with an underlying medical condition, including those with a disability
Other critical and high risk workers. Phase 2b –Astra Zeneca vaccine (transport and storage 2 – 8 degrees Celsius) 15-minute observation expected ALL SUBJECT TO TGA APPROVAL
Remainder of the population
Catch up on people who have missed out<br>
slide8. Phase 3 – VACCINE Yet to be determined
People <18 YO (subject to further TGA approval)<br>
slide9. LIMITING FACTOR = Supply of vaccines
AIM = Delivery in volume and at pace aimed to the target cohort
Current advice 2 doses require 21 days / month apart must be same product
FREE for patient MBS Items and PIP (Exempt from 80/20 rule) GP and OMP
Co-billing being clarified
(no item number for authorised nurse immunisers)
Voluntary<br>
slide10. Selection criteria, processes and outcomes
The Commonwealth Department of Health will receive and review all EOIs according to the following criteria:
1. Capability: Accredited general practices who can provide safe vaccination services according to the specifications in Attachment A and willingness to undertake COVID-19 vaccination specific training.
2. Capacity and volume: Ability to administer, track, record, store, maintain and manage vaccination services with equitable access to all eligible people on a large scale, as per the site specifications outlined in Attachment A.
3. Lead Time: Ability to accelerate administration of vaccination services to meet nominated timeframes.
4. Population coverage and access: Additional consideration will be placed on practices servicing populations in low-access geographic areas or with specific access needs.<br>
slide11. Role of the Primary Health Networks
Primary Health Networks will assist in the coordination, planning and delivery of the vaccine roll-out, including playing a key liaison and support role with general practices. This will include collating and prioritising applications for consideration by the Department of Health according to preparedness (as nominated by the practice), providing information on local context and needs that will help to improve geographic coverage, and liaising with local and jurisdictional health authorities to minimise duplication of services.
Commonwealth DoH will ultimately decide<br>
slide12. OPT in
@1710 hrs 27/01/2020
70 EOI’s in the HNECC PHN region
1500 EOI’s nationally First submission @ 0946 23 January<br>
slide13. Known
Currently 1 Hub for 1a in the Hunter
Practice can withdraw EOI
Change or amend EOI by resubmitting and letting PHN know
Where practices want to pool resources, all should EOI and note this in the free text of all EOI’s seeking to collaborate Question 37 and 42
Unknown
Details on National booking system (this will be available by end of week)
Co-billing clarification in FAQ<br>
slide14. Resources and local
1. link to the NSW Health/RACGP Covid19 Update webinar on the COVID19 Vaccine held on 18 January 2021
– well worth grabbing a coffee or tipple of choice and watching it!
https://youtu.be/GxzgP-rh8Hk
2. Australia’s COVID19 Vaccine National Roll-Out Strategy for Phases of roll out priority groups & stratification
https://www.health.gov.au/sites/default/files/documents/2021/01/australia-s-covid-19-vaccine-national-roll-out-strategy.pdf
3. Central Coast GPs please join our Central Coast GP COVID Community of Practice as we focus on sharing vaccine planning and preparation. Lots of brainstorming to do! Entry via Basecamp:
https://3.basecamp.com/4489790/join/CgP7Fu2gz6kC
Contact Elly Warren or Karen Douglas if you have difficulty registering or have any questions and we will add you manually.
ewarren357@gmail.com
k.douglas1@bigpond.com<br>
slide15. Questions<br>